THE USE OF THE SCOUT DEVICE IN EVALUATION OF DISBETES RISK IN WOMEN WITH PCOS

使用 SCOUT 设备评估 PCOS 女性糖尿病风险

• 批准号: 7952013
• 负责人: Vanita Aroda
• 金额: $ 0.17万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952013
• 关键词: Advanced Glycosylation End Products; Affect; Age; Blood; Blood Pressure; Cholesterol; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Devices; Diabetes Mellitus; Disease; Evaluation; Fluorescence; Funding; Glycosylated hemoglobin A; Gold; Grant; Gynecologist; Hormonal; Hyperinsulinism; Institution; Measures; Medical; Metabolic; Methods; Non-Insulin-Dependent Diabetes Mellitus; OGTT; Obesity; Polycystic Ovary Syndrome; Population; Population Control; Prediabetes syndrome; Primary Health Care; Protocols documentation; Provider; Questionnaires; Research; Research Personnel; Resources; Risk; Risk Assessment; Screening procedure; Sensitivity and Specificity; Skin; Source; Testing; United States National Institutes of Health; Woman; cardiovascular risk factor; diabetes risk; fasting plasma glucose; high risk; preference; reproductive

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Polycystic ovary syndrome (PCOS) is a common disorder affecting 6-10% of women reproductive age. Women with PCOS are at significantly higher risk of developing prediabetes and type 2 diabetes (DM2) compared to age- and BMI-matched women. Pre-diabetes and DM2 are frequently underdiagnosed in this population. Women with PCOS often seek medical advice from their obstetrician/gynecologists or primary care providers who may not order additional tests to evaluate their diabetes risk. This protocol explores the use of a noninvasive investigational diabetes screening device (SCOUT) to evaluate diabetes risk in women with PCOS and an age and BMI-matched control population. The SCOUT noninvasively measures skin fluorescence due to the presence of advanced glycation end products (AGE). AGEs are known to be elevated in people with prediabetes and diabetes, as wells as in women with PCOS. This method will be compared to the gold standard method of an oral glucose tolerance test (OGTT) used to evaluate for prediabetes and diabetes. Sensitivity and specificity will be calculated in comparison to the OGTT in addition to other methods of diabetes risk assessment (fasting plasma glucose, HbA1c). Blood pressure, cholesterol levels, and blood markers of diabetes and cardiovascular risk will also be measured. Questionnaires to evaluate patient¿s preference of diabetes risk assessment will be included. Finally, the risk score provided by skin fluorescence will be corrrelated with other metabolic and hormonal abnormalitities in PCOS (increased adiposity, hyperandrogenemia, hyperinsulinemia, hypoadiponectinemia).

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 多囊卵巢综合征(PCOS)是一种常见疾病，影响6-10%的育龄妇女。与年龄和体重指数匹配的女性相比，患有多囊卵巢综合征的女性患糖尿病前期和2型糖尿病(DM2)的风险显著更高。糖尿病前期和DM2在这一人群中经常被低估。患有多囊卵巢综合征的妇女通常向她们的产科/妇科医生或初级保健提供者寻求医疗建议，这些医生可能不会要求额外的测试来评估她们患糖尿病的风险。该方案探索使用非侵入性调查性糖尿病筛查设备(SCOUT)来评估患有多囊卵巢综合征的女性以及年龄和体重指数匹配的对照组人群的糖尿病风险。由于高级糖基化终末产物(AGE)的存在，童子军非侵入性地测量皮肤荧光。众所周知，患有糖尿病前期和糖尿病的人以及患有多囊卵巢综合征的女性的年龄都会增加。该方法将与用于评估糖尿病前期和糖尿病的口服葡萄糖耐量试验(OGTT)的金标准方法进行比较。除了其他糖尿病风险评估方法(空腹血糖，HbA1c)外，还将计算灵敏度和特异度，并与OGTT进行比较。还将测量血压、胆固醇水平以及糖尿病和心血管风险的血液标记物。将包括评估患者S对糖尿病风险评估的偏好的问卷。最后，皮肤荧光提供的风险评分将与PCOS的其他代谢和激素异常(肥胖症增加、高雄激素血症、高胰岛素血症、低脂联素血症)相关。